Barclays Portfolio holdings
Barclays PLC, founded in 1690 by goldsmith bankers in London, is a British multinational financial institution headquartered in London, operating as one of the world’s oldest banks with a significant presence in investment banking, retail banking, and wealth management. Managing billions in assets, Barclays serves millions of customers globally through its retail arm (notably in the UK) and its investment banking division, which excels in trading, mergers and acquisitions, and capital markets, competing with Wall Street giants. The bank has navigated challenges like the 2008 financial crisis—opting for private funding over a government bailout—and has since focused on restructuring, digital innovation, and sustainable finance initiatives. With a rich history and a modern global footprint, Barclays remains a key player in both UK and international financial markets.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
CRH
CRH
|
+$2.05B |
| 2 |
Texas Instruments
TXN
|
+$1.69B |
| 3 |
NVIDIA
NVDA
|
+$1.36B |
| 4 |
Starbucks
SBUX
|
+$1.2B |
| 5 |
State Street Consumer Discretionary Select Sector SPDR ETF
XLY
|
+$949M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Apple
AAPL
|
+$2.77B |
| 2 |
Microsoft
MSFT
|
+$1.3B |
| 3 |
Alphabet (Google) Class C
GOOG
|
+$1.22B |
| 4 |
iShares US Real Estate ETF
IYR
|
+$1.11B |
| 5 |
Procter & Gamble
PG
|
+$915M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 22.33% |
| 2 | Consumer Discretionary | 7.25% |
| 3 | Financials | 7.18% |
| 4 | Communication Services | 6.16% |
| 5 | Healthcare | 5.91% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1676
PUT
Palantir
PLTR
$301B
| $3.8M | ﹤0.01% |
150,000
-785,000
| -84% | -$17.7M |
|
1677
Coherus Oncology
CHRS
$222M
| $3.79M | ﹤0.01% |
2,190,521
+125,170
| +6% | +$252K |
|
|
AVDL
1678
DELISTED
Avadel Pharmaceuticals
AVDL
| $3.79M | ﹤0.01% |
+269,261
| New | +$4.39M |
|
1679
Allison Transmission
ALSN
$9.65B
| $3.78M | ﹤0.01% |
49,783
-30,750
| -38% | -$2.36M |
|
1680
Essential Properties Realty Trust
EPRT
$6.74B
| $3.78M | ﹤0.01% |
136,292
-24,803
| -15% | -$661K |
|
1681
CALL
Vaxcyte
PCVX
$7.73B
| $3.78M | ﹤0.01% |
50,000
| – | – |
|
1682
Douglas Emmett
DEI
$1.99B
| $3.76M | ﹤0.01% |
282,793
+120,530
| +74% | +$1.63M |
|
|
SKX
1683
DELISTED
Skechers
SKX
| $3.76M | ﹤0.01% |
54,449
-88,535
| -62% | -$5.86M |
|
1684
First Hawaiian
FHB
$3.41B
| $3.76M | ﹤0.01% |
181,011
+23,562
| +15% | +$495K |
|
1685
U-Haul Holding Co Series N
UHAL.B
$12.4B
| $3.76M | ﹤0.01% |
62,592
-4,206
| -6% | -$265K |
|
|
RNAM
1686
DELISTED
Avidity Biosciences
RNAM
| $3.75M | ﹤0.01% |
91,794
-32,152
| -26% | -$923K |
|
1687
PVH
PVH
$4.09B
| $3.74M | ﹤0.01% |
35,321
-24,406
| -41% | -$2.76M |
|
1688
CALL
Guidewire Software
GWRE
$13.1B
| $3.72M | ﹤0.01% |
27,000
| – | – |
|
1689
CALL
Strategy Inc
MSTR
$34.7B
| $3.72M | ﹤0.01% |
+27,000
| New | +$3.89M |
|
|
TEM
1690
Tempus AI
TEM
$8.31B
| $3.71M | ﹤0.01% |
+106,000
| New | +$3.25M |
|
1691
Sonoco
SON
$5.58B
| $3.71M | ﹤0.01% |
73,086
-24,394
| -25% | -$1.41M |
|
|
MZTI
1692
The Marzetti Company
MZTI
$3.04B
| $3.7M | ﹤0.01% |
19,600
-21,545
| -52% | -$4.11M |
|
1693
Pliant Therapeutics
PLRX
$64.4M
| $3.69M | ﹤0.01% |
342,924
-17,221
| -5% | -$222K |
|
1694
The Ensign Group
ENSG
$10.3B
| $3.68M | ﹤0.01% |
29,774
-29,447
| -50% | -$3.51M |
|
|
OSG
1695
Octave Specialty Group
OSG
$255M
| $3.68M | ﹤0.01% |
287,239
+158,203
| +123% | +$2.41M |
|
|
GTLS
1696
DELISTED
Chart Industries
GTLS
| $3.68M | ﹤0.01% |
25,509
-50,068
| -66% | -$7.56M |
|
1697
BrightSpring Health Services
BTSG
$12B
| $3.66M | ﹤0.01% |
322,092
+30,733
| +11% | +$336K |
|
|
SWTX
1698
DELISTED
SpringWorks Therapeutics
SWTX
| $3.66M | ﹤0.01% |
97,031
+24,252
| +33% | +$1.02M |
|
1699
Gibraltar Industries
ROCK
$1.37B
| $3.65M | ﹤0.01% |
53,307
+9,789
| +22% | +$713K |
|
1700
CALL
Arcturus Therapeutics
ARCT
$171M
| $3.65M | ﹤0.01% |
+150,000
| New | +$4.55M |
|
Similar funds
Barclays's Q2 2024 Portfolio in Review
As of Q2 2024, Barclays held 5,455 positions worth $327B, up 14% from $288B the previous quarter. Its ten largest holdings account for 42% of the portfolio.
Barclays deployed $29.4B of net new capital in Q2 2024, opening 406 new positions and adding to 1,053 existing holdings. Its largest new stake was Ferrovial N.V. Ordinary Shares: 4,837,593 shares worth $186M.
By sector, the portfolio is most concentrated in Technology at 22% of assets, down from 24% a quarter earlier, followed by Consumer Discretionary and Financials.
On the sell side, the largest reduction was Apple, an estimated $2.77B trimmed.
- Barclays's largest Q2 2024 buy was Ferrovial N.V. Ordinary Shares: 4,837,593 shares worth $186M.
- Barclays added most to CRH in Q2 2024, an estimated $2.05B increase.
- Barclays's biggest Q2 2024 reduction was Apple, cutting an estimated $2.77B.
- Barclays fully exited Pioneer Natural Resource Co. in Q2 2024, selling an estimated $212M.
- Barclays's ten largest holdings make up 42% of its $327B portfolio in Q2 2024.
- Barclays opened 406 new positions and closed 646 in Q2 2024.
- Barclays's portfolio value rose 14% quarter-over-quarter to $327B.
Based on Barclays's 13F filing for Q2 2024, filed 14 Aug 2024.